Denise D Correa1, Jaya Satagopan2, Kenneth Cheung2, Arshi K Arora2, Maria Kryza-Lacombe2, Youming Xu2, Sasan Karimi2, John Lyo2, Lisa M DeAngelis2, Irene Orlow2. 1. Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (D.D.C., M.K.-L., L.M.D.); Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York (J.S., K.C., A.K.A., Y.X., I.O.); Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York (S.K., J.L.); Department of Neurology and Neuroscience, Weill Cornell Medical College, New York, New York (D.D.C., L.M.D.) corread@mskcc.org. 2. Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (D.D.C., M.K.-L., L.M.D.); Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York (J.S., K.C., A.K.A., Y.X., I.O.); Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York (S.K., J.L.); Department of Neurology and Neuroscience, Weill Cornell Medical College, New York, New York (D.D.C., L.M.D.).
Abstract
BACKGROUND: Cognitive dysfunction is common among patients with brain tumors and can be associated with the disease and treatment with radiotherapy and chemotherapy. However, little is known about genetic risk factors that may moderate the vulnerability for developing cognitive dysfunction. In this study, we examined the association of single nucleotide polymorphisms (SNPs) in the catechol-O-methyl transferase (COMT), brain-derived neurotrophic factor (BDNF), and dystrobrevin-binding protein 1 (DTNBP1) genes with cognitive functions and neuroimaging outcomes in patients with brain tumors. METHODS: One hundred and fifty patients with brain tumors completed neuropsychological tests of attention, executive functions, and memory and were genotyped for polymorphisms in the COMT, BDNF, and DTNBP1 genes. Ratings of white matter (WM) abnormalities on magnetic resonance imaging scans were performed. RESULTS: Multivariate regression shrinkage analyses, adjusted for age, education, treatment type, time since treatment completion, and tumor location, indicated a significant association between the COMT SNP rs4680 (Val158Met) and memory with lower scores in delayed recall (P < .01) among homozygotes (valine/valine). Additional COMT, BDNF and DTNBP1 SNPs were significantly associated with attention, executive functions, and memory scores. CONCLUSION: This is the first study to suggest that known and newly described polymorphisms in genes associated with executive and memory functions in healthy individuals and other clinical populations may modulate cognitive outcome in patients with brain tumors.
BACKGROUND:Cognitive dysfunction is common among patients with brain tumors and can be associated with the disease and treatment with radiotherapy and chemotherapy. However, little is known about genetic risk factors that may moderate the vulnerability for developing cognitive dysfunction. In this study, we examined the association of single nucleotide polymorphisms (SNPs) in the catechol-O-methyl transferase (COMT), brain-derived neurotrophic factor (BDNF), and dystrobrevin-binding protein 1 (DTNBP1) genes with cognitive functions and neuroimaging outcomes in patients with brain tumors. METHODS: One hundred and fifty patients with brain tumors completed neuropsychological tests of attention, executive functions, and memory and were genotyped for polymorphisms in the COMT, BDNF, and DTNBP1 genes. Ratings of white matter (WM) abnormalities on magnetic resonance imaging scans were performed. RESULTS: Multivariate regression shrinkage analyses, adjusted for age, education, treatment type, time since treatment completion, and tumor location, indicated a significant association between the COMT SNP rs4680 (Val158Met) and memory with lower scores in delayed recall (P < .01) among homozygotes (valine/valine). Additional COMT, BDNF and DTNBP1 SNPs were significantly associated with attention, executive functions, and memory scores. CONCLUSION: This is the first study to suggest that known and newly described polymorphisms in genes associated with executive and memory functions in healthy individuals and other clinical populations may modulate cognitive outcome in patients with brain tumors.
Authors: Heather A Wishart; Robert M Roth; Andrew J Saykin; C Harker Rhodes; Gregory J Tsongalis; Kristine A Pattin; Jason H Moore; Thomas W McAllister Journal: J Int Neuropsychol Soc Date: 2010-12-10 Impact factor: 2.892
Authors: Ji Hyun Baek; Ji Sun Kim; Seunghyong Ryu; Sohee Oh; Jihae Noh; Woo Kyeong Lee; Taesung Park; Yu-Sang Lee; Dongsoo Lee; Jun Soo Kwon; Kyung Sue Hong Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2012-08-22 Impact factor: 3.568
Authors: Michael F Egan; Masami Kojima; Joseph H Callicott; Terry E Goldberg; Bhaskar S Kolachana; Alessandro Bertolino; Eugene Zaitsev; Bert Gold; David Goldman; Michael Dean; Bai Lu; Daniel R Weinberger Journal: Cell Date: 2003-01-24 Impact factor: 41.582
Authors: Nancy A Dennis; Anna C Need; Kevin S LaBar; Sheena Waters-Metenier; Elizabeth T Cirulli; James Kragel; David B Goldstein; Roberto Cabeza Journal: Cereb Cortex Date: 2009-07-29 Impact factor: 5.357
Authors: F Miyajima; W Ollier; A Mayes; A Jackson; N Thacker; P Rabbitt; N Pendleton; M Horan; A Payton Journal: Genes Brain Behav Date: 2007-10-31 Impact factor: 3.449
Authors: Katie M O'Brien; Irene Orlow; Cristina R Antonescu; Karla Ballman; Linda McCall; Ronald DeMatteo; Lawrence S Engel Journal: PLoS One Date: 2013-04-18 Impact factor: 3.240
Authors: D D Correa; J C Root; M Kryza-Lacombe; M Mehta; S Karimi; M L Hensley; N Relkin Journal: Brain Imaging Behav Date: 2017-12 Impact factor: 3.978
Authors: Renke Zhou; Jeffrey S Wefel; Erik P Sulman; Nicholas S Boehling; Georgina N Armstrong; Spiridon Tsavachidis; Fu-Wen Liang; Carol J Etzel; Lisa S Kahalley; Brent J Small; Michael E Scheurer; Melissa L Bondy; Yanhong Liu Journal: J Neurooncol Date: 2021-11-24 Impact factor: 4.130
Authors: D D Correa; M Kryza-Lacombe; X Zhou; R E Baser; B J Beattie; Z Beiene; J Humm; L M DeAngelis; I Orlow; W Weber; J Osborne Journal: J Neurooncol Date: 2017-11-22 Impact factor: 4.130
Authors: David B Altshuler; Lin Wang; Lili Zhao; Zachary Miklja; Joey Linzey; Amanda Brezzell; Sofia Kakaizada; Saritha Krishna; Daniel A Orringer; Emily M Briceño; Nicolette Gabel; Shawn L Hervey-Jumper Journal: Neurooncol Pract Date: 2019-04-10
Authors: Huimin Geng; Mazie Tsang; Lakshmipriya Subbaraj; Joseph Cleveland; Lingjing Chen; Ming Lu; Jigyasa Sharma; Daniel B Vigneron; John Kurhanewicz; Marisa LaFontaine; Tracy Luks; Bruce A Barshop; Jon Gangoiti; Javier E Villanueva-Meyer; James L Rubenstein Journal: Neuro Oncol Date: 2021-10-01 Impact factor: 12.300